Introduction
Nocturnal frontal lobe epilepsy (NFLE) comprises a complex spectrum of distinct paroxysmal sleep-related attacks of variable intensity, including paroxysmal arousals, nocturnal paroxysmal dystonias and epileptic nocturnal wanderings. Scalp EEG and brain MRI are unable to reveal abnormalities in a considerable amount of patients. 1 In those cases the epileptic nature of NFLE is supported by the stereotypical clinical presentation of the episodes and the often dramatic response to antiepileptic drugs (AEDs) like Carbamazepine, Clonazepam or Topiramate. Spinocerebellar ataxia type 17 (SCA 17) is a neurodegenerative disease caused by the expansion above 44 units of a CAG/CAA repeat in the coding region of the TATA box binding protein (TBP) gene. It is one of the rarer forms amongst autosomal dominant cerebellar ataxias, with extreme variable age at onset and clinical phenotype. 2 Epilepsy is quite commonly observed among SCA 17 patients, however it is exclusively described in terms of generalized tonic-clonic seizures. 3 We report a case of NFLE occurring in a SCA 17 patient and brilliantly responsive to Topiramate after failure of the first line therapy with Carbamazepine.
Case description
A 35 year-old man developed a subtle, slowly progressive ataxic syndrome, in the presence of a positive family history for SCA 17. Genetic research for polyglutamine stretch expansion in the TBP gene showed a 52 CAG triplet repetition.
Two years later he came to our neurological clinic, complaining of a 8-month history of hyperkinetic nocturnal spells, which were characterized by complex motor behavior involving upper as well as lower extremities and were associated with unintelligible moaning. Sometimes motor activity caused injury to the bed partner or to the patient himself due to falls out of bed. He could never recall the episodes the morning after and he always reported a good subjective quality of sleep.
There was no family history of nocturnal events. Neurological examination on admission showed mild ataxia, dysarthria and abnormalities in conjugated ocular movements. Neuropsychological tests revealed a moderate degree of cognitive decline (Wechsler Adult Intelligence Scale total IQ 55, verbal IQ 63, performance IQ 55). Memory function was relatively spared, while attention, planning and thought organization were all severely affected. Brain MRI demonstrated diffuse mild-entity parenchimal atrophy, which involved mainly the cerebellum. No focal alterations were recognizable. A brain PET scan revealed a left cerebellar hypoperfusion, but no supratentorial abnormalities. The awake scalp EEG was unremarkable. During an all night video-polysomnographic recording (EEG, 10-20 International System; electro-oculography, surface EMG of submental muscle, EKG) we recorded 12 stereotyped episodes characterized by initial left arm elevation above or in front of the head, then followed by right arm flexion with slight waving of the hand, sometimes accompanied by lower extremities movements (see Video 1 online). The patient always returned back to sleep immediately thereafter. Spells lasted between 8 and 25 s and occurred mainly during N2 stage. The polygraphic recording during the attacks was completely obscured by the huge movement artifacts, yet heart rate acceleration compared to the baseline was recognizable (Fig. 1) .
The patient was started on Carbamazepine up to 800 mg without evident clinical benefit. Topiramate was then prescribed at a starting dose of 50 mg, which completely abolished the attacks. Unfortunately, ataxia significantly worsened despite the low dose. Therefore Topiramate was reduced to 25 mg. Ataxic symptoms improved, but seizure sporadically reappeared.
Discussion
Symptoms in SCA 17 have typically their onset in third or fourth decade. The presenting features may be either psychiatric disturbances, such as behavioral changes and mood alterations, or neurological signs, like ataxia and movement disorders. Dementia is a frequent and early complaint. Epilepsy is observed in about 35% of patients and is usually a late feature. [3] [4] [5] Literature descriptions are restricted to generalized tonic-clonic seizures. [4] [5] [6] No distinctive epileptic syndrome has been recognized yet. Patient's nocturnal attacks can fit the definition of paroxysmal arousals.
1 Their epileptic origin is highly probable because of the following features: the stereotypical nature of the events, their very high nightly recurrence rate, which is distinctly unusual for parasomnias, and the response to AED treatment. Furthermore, the neuropsychological assessment, although unable to lateralize, pointed out to a predominant frontal lobe dysfunction, in keeping with the localization hypothesis for the disease.
To the best of our knowledge, there are not currently descriptions of NFLE in SCA 17 patients. Our case might merely be the result of a casual association between two uncommon diseases, although some clinical-pathological correlations raise the possibility of a physiopathological substrate for this peculiar epileptic syndrome occurrence in this kind of neurodegenerative disease. Indeed, neuropathological studies show diffuse brain atrophy, which predominates in the cerebellum but is also significant in the fronto-temporal cortex and caudate nucleus. 2, 3 The diffuse alterations of frontal cortical and subcortical networks may be held responsible for the early behavioral changes and cognitive deficits seen in the large majority of SCA 17 patients, 2, 4 and as for our subject, they could justify the development of an epileptic circuitry in those areas. Topiramate is a wide spectrum AED, with multiple mechanisms of action: it enhances gamma aminobuthyrric acid transmission and modulates the excitability of sodium and calcium voltagegated channels. It is known to be effective in new-onset partial epilepsies as well as in refractory partial and generalized epilepsies. Recently, its efficacy has been proved in NFLE, where it seems effective either as monotherapy or as an add on drug to Carbamazepine, even with low doses. 7 Ataxia is not an uncommon side effect of Topiramate, but it is usually secondary to high dosages. 8 The presence of a significant underlying cerebellar dysfunction, which was demonstrated by the brain PET scan findings, might have contributed to the abnormal susceptibility of this patient for the development of that side effect.
Conclusions
SCA 17 is a rare neurodegenerative disease which has a wide phenotype and spectrum of presentations. Seizures are frequently described, but without any further specification. This case contributes to the definition of the possible epileptic syndromes associated with this disease and broadens its clinical picture.
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